UPDATE: Jefferies Raises PT on Abbott Laboratories on In-Line Q1'13 Results, Strong Outlook

In a report published Friday, Jefferies analyst Jeffrey Holford reiterated a Buy rating on Abbott Laboratories ABT, and slightly raised the price target from $42.00 to $43.00. In the report, Holford noted, “Q1'13 results were mostly in line despite some lingering pressures in Established Pharma and Medical Devices from 2012. These should annualize before H2'13, exposing strong underlying growth. Meanwhile Nutrition continues to deliver and we are increasingly convinced that management may deploy capital towards bolt-on acquisitions in the near future.” Abbott Laboratories closed on Thursday at $36.88.